Risultati della ricerca - O. V. Krokhina

  • Mostra 1 - 3 risultati su 3
Raffina i risultati
  1. 1

    CAPABILITIES OF ONE-STAGE BREAST REPAIR WITH A BECKER EXPANDING ENDOPROSTHESIS di N. R. Fedyanina, V. A. Sobolevsky, O. V. Krokhina, Yu. S. Yegorov, E. M. Nikitina

    Pubblicazione 2014-09-01

    Organ-preserving surgical interventions can be performed owing to improved drug and radiation therapy methods. When radical resec- tion is contraindicated, radical mastectomy is carried out, which is a serious psychological trauma to a woman.In this connection, plastic reparative surgery for breast...

    Descrizione completa

    Testo
    Articolo
  2. 2

    Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer di L. N. Lyubchenko, M. G. Filippova, T. A. Shendrikova, L. G. Zhukova, N. I. Mekhtieva, O. V. Krokhina, S. M. Portnoy

    Pubblicazione 2017-10-01

    Tamoxifen is the drug of choice for endocrine therapy of hormone receptor- positive breast cancer in women in the reproductive period.  The metabolic activity of tamoxifen is determined by the activity of the enzyme CYP2D6, encoded by the gene of the same name: under  the action of the enzyme, tamox...

    Descrizione completa

    Testo
    Articolo
  3. 3

    Hereditary breast cancer: genetic and clinical hetergeneity, genetic testing, prophylactic surgery di L. N. Lyubchenko, Ye. I. Bateneva, I. K. Vorotnikov, S. M. Portnoy, O. V. Krokhina, V. A. Sobolevskiy, L. G. Zhukova, V. A. Khaylenko, S. A. Tyulyandin

    Pubblicazione 2015-06-01

    5–10 % of breast cancer cases are hereditary, 30 % of them are caused by BRCA1 and BRCA2 mutations (breast / ovarian cancer syndrome). Average cumulative risks of breast and ovarian cancer in BRCA1 mutation carriers run up to 87 % and 44 %, correspondingly. The risk for contralateral breast cancer i...

    Descrizione completa

    Testo
    Articolo